BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. Oncotarget 2017;8:104615-37. [PMID: 29262666 DOI: 10.18632/oncotarget.18403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Gorain B, Bhattamishra SK, Choudhury H, Nandi U, Pandey M, Kesharwani P. Overexpressed Receptors and Proteins in Lung Cancer. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Elsevier; 2019. pp. 39-75. [DOI: 10.1016/b978-0-12-815720-6.00003-4] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Moody TW, Ramos-Alvarez I, Jensen RT. Neuropeptide G Protein-Coupled Receptors as Oncotargets. Front Endocrinol (Lausanne) 2018;9:345. [PMID: 30008698 DOI: 10.3389/fendo.2018.00345] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
3 Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, Neil MO, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene 2020;39:1231-45. [PMID: 31616061 DOI: 10.1038/s41388-019-1059-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
4 Hsu PC, Yang CT, Jablons DM, You L. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers (Basel) 2020;12:E1361. [PMID: 32466572 DOI: 10.3390/cancers12061361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]